Incidence of adverse events (AEs) in patients with CLL and NHL.
| CLL | NHL | |||
|---|---|---|---|---|
| Hematologic AEs | Grade 3–4, N (%) | Any grade, N (%) | Grade 3–4, N (%) | Any grade, N (%) |
| Anemia | 0 (0) | 1 (9.1) | 0 (0) | 0 (0) |
| Thrombocytopenia | 0 (0) | 2 (18.1) | 1 (4.8) | 2 (9.5) |
| Neutropenia | 0 (0) | 2 (18.1) | 1 (4.8) | 1 (4.8) |
| Lymphocytosis | 0 (0) | 2 (18.1) | 0 (0) | 2 (9.5) |
| Non-hematologic AEs | ||||
| Diarrhea | 1 (9.1) | 3 (27.3) | 2 (9.5) | 8 (38.1) |
| Pneumonia | 3 (27.3) | 3 (27.3) | 1 (4.8) | 5 (23.8) |
| Hemorrhage | 0 (0) | 1 (9.1) | 0 (0) | 0 (0) |
| Atrial fibrillation | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Blood Res 2020;55:206~212 https://doi.org/10.5045/br.2020.2020158
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd